Initiate Phase 1 clinical trial of ADX-246 and Phase 1/2 clinical trial of ADX-248
Not delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 9 Mar 2023
- Due
- 31 Mar 2024
- Checked
- 5 Oct 2026
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“a Phase 1 clinical trial of orally administered ADX‑246 for the treatment of systemic immune-mediated diseases, and a Phase 1/2 clinical trial of intravitreally injected ADX‑248... are expected to initiate in the second half of”
What we found
Evidence strength A What the grades mean
No evidence trials initiated by early 2024 deadline. IND applications submitted but trial initiations pushed to H2 2024 or 2026.
-
A Aldeyra Therapeutics Provides Clinical and Regulatory Update - January 2024
“an IND application of next-generation investigational RASP modulator ADX-246 for a Phase 1 clinical trial in healthy volunteers has been submitted to the FDA and is expected to be expanded to include clinical testing in patients with atopic dermatitis. The clinical trial is anticipated to be initiat” ✓ confirmed on the page
-
B Aldeyra Announces New RASP Modulators at 2024 Investor Roundtable
“ADX-248 will be advanced in lieu of ADX-246 to Phase 1/2 clinical testing in atopic dermatitis. Phase 1 clinical testing of ADX-248 is expected to begin in the second half of 2024.”
-
D Aldeyra Therapeutics Annual Report - February 2026
“Clinical trials of next-generation RASP modulators ADX-248 (oral administration) and ADX-246 (intravitreal injection) in atopic dermatitis and the dry form of age-related macular degeneration (dry AMD) are expected to be initiated in 2026” ✓ confirmed on the page
Checked 5 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Initiate
- Deliverable
- Phase 1 and Phase 1/2 clinical trials
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- Medium
- Conditional
- Yes: Pending completion of Investigational New Drug requirements
- Depends on
- Regulatory
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Gemini (Google), re-read the evidence without being told the outcome and reached the same answer.
- Third check on a negative finding: agreesBecause a negative finding could harm a company if wrong, a stronger model re-read the evidence fully blind and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Aldeyra Therapeutics, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2023-ALDX-003508 · Corrections policy